ACADIA PHARMACEUTICALS INCACAD
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income (loss) | - | - | - | - | - | - | - | -245 | -235 | -282 | -168 | -216 | -61 | 226 |
|---|
| Stock-based compensation | 2 | 2 | 6 | - | 40 | 55 | 76 | 82 | 82 | 84 | 64 | 68 | 66 | 67 |
|---|
| Amortization of premiums and accretion of discounts on investment securities | - | 0 | -2 | -0 | 2 | -0 | 0 | 1 | 4 | -1 | -2 | 3 | 8 | 9 |
|---|
| Amortization of intangible assets | - | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | 4 | 15 |
|---|
| Gain on sale of non-financial asset | - | - | - | - | - | - | - | - | - | - | - | - | - | 147 |
|---|
| Gain on strategic investment | - | - | - | - | - | - | - | -2 | 1 | -1 | 2 | 4 | 5 | - |
|---|
| Depreciation | 0 | 0 | - | - | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 1 |
|---|
| Loss on sale of investment securitie | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - |
|---|
| Accounts receivable, net | - | - | - | - | - | 6 | 11 | 9 | 10 | 12 | 16 | -2 | 36 | 0 |
|---|
| Interest and other receivables | - | - | - | 0 | 1 | -0 | -0 | 1 | 0 | -0 | -1 | -0 | 3 | 2 |
|---|
| Inventory | - | - | - | - | - | 3 | 1 | -2 | 2 | 3 | 4 | -2 | 29 | 50 |
|---|
| Prepaid expenses and other current assets | 0 | -0 | 2 | -1 | 1 | 5 | 1 | 12 | -2 | 7 | -2 | -2 | 18 | 17 |
|---|
| Operating lease right-of-use assets | - | - | - | - | - | - | - | - | -4 | -4 | -6 | -7 | -6 | -8 |
|---|
| Other assets | -0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 |
|---|
| Accounts payable | -0 | -1 | -1 | 2 | -0 | 2 | 5 | -6 | 4 | 1 | -2 | 6 | 5 | -1 |
|---|
| Accrued liabilities | 0 | 1 | 2 | 7 | 6 | 16 | 4 | 16 | 6 | 28 | -8 | 24 | 93 | 71 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | - | - | -3 | -2 | -5 | -8 | -6 | -8 |
|---|
| Long-term liabilities | -0 | - | 0 | 0 | 0 | -0 | 0 | 1 | 1 | 2 | 2 | 2 | 6 | 3 |
|---|
| Net cash provided by (used in) operating activities | -20 | -22 | - | - | - | - | - | -167 | -151 | -136 | -126 | -114 | 17 | 158 |
|---|
| Purchases of investment securities | 48 | - | - | - | - | - | - | - | - | - | 493 | 363 | 370 | 505 |
|---|
| Sale and maturity of investment securities | - | 31 | 86 | 248 | 419 | 431 | 572 | 262 | 414 | 540 | 423 | 436 | 430 | 329 |
|---|
| Proceeds from sale of non-financial asset | - | - | - | - | - | - | - | - | - | - | - | - | - | 147 |
|---|
| Proceeds from sales of strategic investment | - | - | - | - | - | - | - | - | - | - | - | - | 12 | - |
|---|
| Net purchases of property and equipment | - | - | 1 | 0 | 2 | 2 | 1 | 2 | 1 | 8 | 1 | - | 0 | 1 |
|---|
| Intangible assets | - | - | - | - | - | - | - | - | - | - | - | - | 40 | - |
|---|
| Net cash (used in) provided by investing activities | 6 | -26 | - | - | - | - | - | -71 | -166 | 193 | -71 | 73 | 32 | -31 |
|---|
| Proceeds from Issuance of Common Stock | 14 | 98 | 112 | 204 | 15 | 519 | 31 | 307 | 372 | 81 | 18 | 8 | 25 | 7 |
|---|
| Net cash provided by financing activities | 14 | 98 | - | - | - | - | - | 307 | 372 | 81 | 18 | 8 | 25 | 7 |
|---|
| Effect of exchange rate changes on cash | - | - | - | - | - | - | - | 0 | 0 | -0 | 0 | 0 | -0 | -0 |
|---|
| Net increase (decrease) in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | 68 | 55 | 137 | -179 | -33 | 74 | 134 |
|---|
| Income Taxes Paid, Net | - | - | - | - | 0 | 0 | 1 | -1 | 2 | 1 | 1 | 2 | 6 | 20 |
|---|
| Accrued inventory purchases | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Noncash or Part Noncash Acquisition, Fixed Assets Acquired | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 30 | 99 |
|---|
| Stock Issued During Period, Value, Issued for Services | - | - | - | - | - | - | - | - | - | 44 | - | - | - | - |
|---|